We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) closed the most recent trading day at $238.11, moving -2.09% from the previous trading session. This change lagged the S&P 500's 0.25% gain on the day. Elsewhere, the Dow gained 0.1%, while the tech-heavy Nasdaq added 0.47%.
Prior to today's trading, shares of the world's biggest maker of health care products had lost 0.11% was narrower than the Medical sector's loss of 4.79% and the S&P 500's loss of 1.88%.
The upcoming earnings release of Johnson & Johnson will be of great interest to investors. The company is predicted to post an EPS of $2.69, indicating a 2.89% decline compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $23.44 billion, reflecting a 7.06% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $11.54 per share and a revenue of $100.36 billion, demonstrating changes of +6.95% and +6.55%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Johnson & Johnson. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.04% upward. At present, Johnson & Johnson boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Johnson & Johnson is currently trading at a Forward P/E ratio of 21.07. This denotes a premium relative to the industry average Forward P/E of 15.23.
It's also important to note that JNJ currently trades at a PEG ratio of 2.4. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 2.1.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 201, finds itself in the bottom 18% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Johnson & Johnson (JNJ) Stock Slides as Market Rises: Facts to Know Before You Trade
Johnson & Johnson (JNJ - Free Report) closed the most recent trading day at $238.11, moving -2.09% from the previous trading session. This change lagged the S&P 500's 0.25% gain on the day. Elsewhere, the Dow gained 0.1%, while the tech-heavy Nasdaq added 0.47%.
Prior to today's trading, shares of the world's biggest maker of health care products had lost 0.11% was narrower than the Medical sector's loss of 4.79% and the S&P 500's loss of 1.88%.
The upcoming earnings release of Johnson & Johnson will be of great interest to investors. The company is predicted to post an EPS of $2.69, indicating a 2.89% decline compared to the equivalent quarter last year. At the same time, our most recent consensus estimate is projecting a revenue of $23.44 billion, reflecting a 7.06% rise from the equivalent quarter last year.
For the full year, the Zacks Consensus Estimates project earnings of $11.54 per share and a revenue of $100.36 billion, demonstrating changes of +6.95% and +6.55%, respectively, from the preceding year.
Investors might also notice recent changes to analyst estimates for Johnson & Johnson. These recent revisions tend to reflect the evolving nature of short-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the business outlook.
Based on our research, we believe these estimate revisions are directly related to near-term stock moves. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has shifted 0.04% upward. At present, Johnson & Johnson boasts a Zacks Rank of #3 (Hold).
In terms of valuation, Johnson & Johnson is currently trading at a Forward P/E ratio of 21.07. This denotes a premium relative to the industry average Forward P/E of 15.23.
It's also important to note that JNJ currently trades at a PEG ratio of 2.4. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As the market closed yesterday, the Large Cap Pharmaceuticals industry was having an average PEG ratio of 2.1.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 201, finds itself in the bottom 18% echelons of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.